tislelizumab + cisplatin + gemcitabine + trilaciclib + Sanofi pneumococcal vaccine

This drug entry represents a composite of two unrelated clinical trial entities: an oncology combination regimen and an investigational pneumococcal vaccine. The oncology portion consists of **tislelizumab** (a PD-1 blocking monoclonal antibody), **cisplatin** (a platinum-based DNA alkylator), **gemcitabine** (a nucleoside metabolic inhibitor), and **trilaciclib** (a transient CDK4/6 inhibitor). This specific four-drug combination has been evaluated in Phase 2 trials (e.g., NCT04863248) for the treatment of locally advanced or metastatic urothelial carcinoma to improve antitumor activity while reducing chemotherapy-induced myelosuppression. The second portion refers to **Sanofi's investigational protein-based pneumococcal vaccines (PPrV)**, such as **SP0202**, which are recombinant protein-based candidates designed to provide broad protection against *Streptococcus pneumoniae* by targeting conserved surface proteins. These vaccines are currently in Phase 1 development for healthy adults. There is no known therapeutic product or clinical trial that combines these five components into a single regimen; the name likely reflects a data integration error.

Other names

PPrV